Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Reid

Showing results (91-100 of 150) with videos related to

Pageof 15
Sort By:
Clinical Drug Investigation|December 14, 2006
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -internationalDavid M Reid, David Hosking, David Kendler, et al.
European Journal of Human Genetics : EJHG|January 12, 2012
Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal womenAlison Gartland, Kristen K Skarratt, Lynne J Hocking, et al.
The Journal of Clinical Endocrinology and Metabolism|August 21, 2012
Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal womenAntonia Hoeg, Apostolos Gogakos, Elaine Murphy, et al.
The Journal of Clinical Endocrinology and Metabolism|June 29, 2006
Haplotypes defined by promoter and intron 1 polymorphisms of the COLIA1 gene regulate bone mineral density in womenTracy L Stewart, Huilin Jin, Fiona E A McGuigan, et al.
The British Journal of Nutrition|October 15, 2014
Patterns of dietary intake and serum carotenoid and tocopherol status are associated with biomarkers of chronic low-grade systemic inflammation and cardiovascular riskAdrian D Wood, Anna A Strachan, Frank Thies, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 16, 2013
Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal womenHelen M Macdonald, Adrian D Wood, Lorna S Aucott, et al.
Circulation|October 13, 2010
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trialKristine Ensrud, Andrea LaCroix, John R Thompson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 25, 2006
Large-scale population-based study shows no association between common polymorphisms of the TGFB1 gene and BMD in womenFiona E A McGuigan, Helen M Macdonald, Amelia Bassiti, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 8, 2004
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS StudyClaus C Glüer, Richard Eastell, David M Reid, et al.
Lancet (London, England)|April 14, 2009
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialDavid M Reid, Jean-Pierre Devogelaer, Kenneth Saag, et al.
Pageof 15

Showing results (91-100 of 150) with videos related to

Sort By:
Pageof 15
Clinical Drug Investigation|December 14, 2006
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -internationalDavid M Reid, David Hosking, David Kendler, et al.
European Journal of Human Genetics : EJHG|January 12, 2012
Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal womenAlison Gartland, Kristen K Skarratt, Lynne J Hocking, et al.
The Journal of Clinical Endocrinology and Metabolism|August 21, 2012
Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal womenAntonia Hoeg, Apostolos Gogakos, Elaine Murphy, et al.
The Journal of Clinical Endocrinology and Metabolism|June 29, 2006
Haplotypes defined by promoter and intron 1 polymorphisms of the COLIA1 gene regulate bone mineral density in womenTracy L Stewart, Huilin Jin, Fiona E A McGuigan, et al.
The British Journal of Nutrition|October 15, 2014
Patterns of dietary intake and serum carotenoid and tocopherol status are associated with biomarkers of chronic low-grade systemic inflammation and cardiovascular riskAdrian D Wood, Anna A Strachan, Frank Thies, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 16, 2013
Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal womenHelen M Macdonald, Adrian D Wood, Lorna S Aucott, et al.
Circulation|October 13, 2010
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trialKristine Ensrud, Andrea LaCroix, John R Thompson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 25, 2006
Large-scale population-based study shows no association between common polymorphisms of the TGFB1 gene and BMD in womenFiona E A McGuigan, Helen M Macdonald, Amelia Bassiti, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 8, 2004
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS StudyClaus C Glüer, Richard Eastell, David M Reid, et al.
Lancet (London, England)|April 14, 2009
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialDavid M Reid, Jean-Pierre Devogelaer, Kenneth Saag, et al.
Pageof 15